SlideShare a Scribd company logo
By:-
Bangladeshi Pal (BDP)
 An ADR as “ a response to a drug that is noxious and unintended and occurs at doses
normally used in man for the prophylaxis , diagnosis or therapy of disease , or for
modification of physiological function ( WHO , 1972 ) .
 Rawlins-Thompson classification
 The Rawlins-Thompson system of classification divides ADRS into two main groups:
Type A and Type B (Rawlins, 1981).
 Type A reactions are the normal, but quantitatively exaggerated, pharmacological
effects of a drug. They include the primary pharmacological effect of the drug, as
well as any secondary pharmacological effects of the drug, for example, ADRS
caused by the antimuscarinic activity of tricyclic antidepressants. Type A reactions
are most common, accounting for 80% of reactions.
Types of reaction Features Examples
Type A: Augmented pharmacological
effect
Common, predictable effect, Dose
dependent, Low morbidity, Low
mortality
Bradycardia associated with a beta-
adrenergic receptor antagonist
Type B: Bizzare effects not related
to pharmacological effect
Uncommon, Unpredictable, Not
dose dependent, High morbidity,
High mortality
Anaphylaxis associated with a
penicillin antibiotic
Type C: Dose-related and time-
related
Uncommon, Related to the
cumulative dose
Hypothalamic pituitary- adrenal axis
suppression by corticosteroids
Type D: Time related Uncommon, Usually dose related,
Occurs or becomes apparent some
time after use of the drug
Carcinogenesis
Type E: Withdrawal Uncommon, Occurs soon after
withdrawal
Opiate withdrawal syndrome
Type F: Unexpected failure of
therapy
Common, Dose- related, Often
cause by drug interactions
Failure of oral contraceptive in
presence of enzyme inducer
Dose relatedness Time relatedness Susceptibility
Toxic effects: ADR S that occur
at doses higher than the usual
therapeutic dose Collateral
effects: ADR s that occur at
standard therapeutic doses
Hyper-susceptibility reactions:
ADRS that occur at sub-
therapeutic doses in susceptible
Patients
Time-independent reactions: ADR s
that occur at any time during
treatment. Time-dependent reactions:
Rapid reactions occur when a drug is
administered too rapidly. Early
reactions occur early in treatment then
abate with continuing treatment
(tolerance). Intermediate reactions
occur after some delay, but if reaction
does not occur after a certain time,
little or no risk exists. Late reactions
risk of ADR increases with continued-
to-repeated exposure, including
withdrawal reactions. Delayed
reactions occur some time after
exposure, even if the drug is withdrawn
before the ADR occurs.
Raised susceptibility may be
present in some individuals,
but not others. Alternatively,
susceptibility may follow a
continuous distribution -
increasing susceptibility with
impaired renal function.
Factors include: genetic
variation, age, sex, altered
physiology, exogenous factors
(interactions) and disease.
A number of general factors which affect susceptibility to ADRS and others which affect
the propensity of specific drugs to cause ADRS have been elucidated.
(i) Age
(ii) Gender
(iii) Co-morbidities and concomitant medicines use
(iv) Ethnicity
(v) Pharmacogenetics
(vi) Erythrocyte glucose-6-phosphatase dehydrogenase (G6PD) deficiency
(vii) Porphyrias
 Elderly patients may be more prone to ADRS, with age- related decline in both the
metabolism and elimination of drugs from the body. They also have multiple cos
morbidities and are, therefore, exposed to more prescribed drugs. Children differ
from adults in their response to drugs. Neonatal differences in body composition,
metabolism and other physiological parameters can increase the risk of specific
adverse reactions. Differences in drug metabolism and elimination and end-organ
responses can also increase the risk. Chloramphenicol, digoxin, and ototoxic
antibiotics such as streptomycin are examples of drugs that have a higher risk of
toxicity in the first weeks of life.
 Women may be more susceptible to ADRS. In addition, there are particular adverse
reactions that appear to be more common in women than men. For example,
impairment of concentration and psychiatric adverse events associated with the
anti-malarial mefloquine are more common in females. Females are more
susceptible to drug-induced torsade de pointes, a ventricular arrhythmia linked to
ventricular fibrillation and death. Women are also over-represented in reports of
torsades de pointes associated with cardiovascular drugs (such as sotalol) and
erythromycin. This increased susceptibility in women is thought to be due to their
longer QTc interval compared to mên.
 In cardiology, the QT interval is a
measure of the time between the start of
the Q wave and the end of the T wave in
the heart's electrical cycle. A lengthened
QT interval is a marker for the potential
of ventricular tachyarrhythmias like
torsades de pointes and a risk factor for
sudden death.
 Torsades de pointes (TdP) is a specific
form of polymorphic ventricular
tachycardia occurring in the context of
QT prolongation; it has a characteristic
morphology in which the QRS complexes
"twist" around the isoelectric line. For
TdP to be diagnosed, the patient has to
have evidence of both PVT and QT
prolongation.
 Reductions in hepatic and renal function substantially increase the risk of ADRSs. A
recent study examining factors that predicted repeat admissions to hospital with
ADRS in older patients showed that co-morbidities such as congestive cardiac
failure, diabetes, and peripheral vascular, chronic pulmonary, rheumatological,
hepatic, renal, and malignant diseases were strong predictors of readmissions for
ADRS, while advancing age was not. Reasons for this could be pharmacokinetic and
pharmacodynamic changes associated with pulmonary, cardiovascular, renal and
hepatic insufficiency, or drug interactions because of multiple drag therapy.
 Ethnicity is the fact or state of belonging to a social group that has a common
national or cultural tradition. It has also been linked to susceptibility to ADRS, due
to inherited traits of metabolism. For example, that the cytochrome P450 genotype,
involved in drug metabolism, has varied distribution among people of differing
ethnicity (CYP2C9 alleles associated with poor metabolism can affect warfarin
metabolism and increase the risk of toxicity). This occurs more frequently in white
individuals compared to black individuals.
- Examples of ADRS linked to ethnicity include the increased risk of angioedema with
the use of ACE inhibitors in black patients,
- the increased propensity of white and black patients to experience central nervous
system ADRS associated with mefloquine compared to patients of Chinese or
Japanese origin,
- differences in the pharmacokinetics of rosuvastatin in Asian patients which may
expose them to an increased risk of myopathy.
 Pharmacogenetics is the study of inherited genetic |differences in drug metabolic
pathways which can affect individual responses to drugs, both in terms of
therapeutic effect as well as adverse effects. It influence an individual's response to
drugs, and examines polymorphisms that code for drug transporters, drug-
metabolising enzymes and drug receptors. Examples of pharmacogenetics are
hypersensitivity reactions to abacavir used in the treatment of HIV and cutaneous
ADRS Steven- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) to
antiepileptic drugs such as carbamazepine and phenytoin.
 Glucose-6-phosphate dehydrogenase deficiency (G6PDD) is an inborn error of
metabolism that predisposes to red blood cell breakdown. Most of the time, those
who are affected have no symptoms. Following a specific trigger, symptoms such as
yellowish skin, dark urine, shortness of breath, and feeling tired may develop.
G6PD deficiency is present in over 400 million people worldwide. It is a sex- linked
inherited enzyme deficiency, leading to susceptibility to haemolytic anaemia.
Patients with low levels of G6PD are predisposed to haemolysis with oxidant drugs
such as primaquine, sulphonamides and nitrofurantoin.
 Porphyrins are a group of heterocyclic macrocycle organic compoupds, composed of
four modified pyrrole subunits interconnected at their a carbon atoms via methine
bridges. These disorders are usually inherited, meaning they are caused by
abnormalities in genes passed from parents to children. When a person has a
porphyria, cells fail to change body chemicals called porphyrins and porphyrin
precursors into heme, the substance that gives blood its red color. The porphyrias
are a heterogeneous group of inherited disorders of haem biosynthesis. The effects
of drugs are of most importance in patients with acute porphyrias, in which certain
commonly prescribed agents may precipitate life-threatening attacks. Other trigger
factors include alcohol and changes in sex hormone balance. In the acute
porphyrias, patients develop abdominal and neuropsychiatric disturbances, and they
excrete in their urine excessive amounts of the porphyrin precursors 5-
aminolaevulinic acid (ALA) and porphobilinogen.
 Immunologic response - a bodily defense reaction that recognizes an invading
substance (an antigen: such as a virus or fungus or bacteria or transplanted organ)
and produces antibodies specific against that antigen. immune reaction, immune
response. The immune system is able to recognize drugs as foreign substances,
leading to allergic reactions. Smaller drug molecules (<600 Da) can bind with
proteins to trigger an immune response, or larger molecules can trigger an immune
response directly. The immune response is not related to the pharmacological action
of the drug and prior exposure to the drug is required. Immunological reactions are
often distinct recognizable responses. Allergic reactions range from rashes, serum
sickness and angioedema to the life-threatening bronchospasm and hypotension
associated with anaphylaxis. Patients with a history of atopic or allergic disorders
are at higher risk. Immunological (hypersensitivity) reactions are split into four main
types.
Classification Mechanism Symptoms/signs and examples
Type I (immediate) Drug/lgE complex to mast cells
release of histamine and
leukotrienes.
Symptoms/signs and examples
Pruritis, urticaria,
bronchoconstriction, angioedema,
hypotension, shock, for example,
penicillin anaphylaxis.
Type II (cytotoxic) IgG and complement binding to
(usually) red blood cell. Cytotoxic T-
cells lyse the cell.
Haemolytic anaemia and
thrombocytopaenia, for example,
associated with cephalosporins,
penicillins and rifampicin.
Type II (immune complex) Drug antigen and I gG or I gM form
immune complex, attracting
macrophages and complement
activation.
Cutaneous vasculitis, serum
sickness, for example, associated
with chlorpromazine and
sulphonamides
Type IV (delayed type) Antigen presentation with major
histocompatibility complex protein
to T-cells and cytokine and
inflammatory mediator release.
Usually occur after 7-20 days.
Macular rashes and organ failure,
including Stevens-Johnson syndrome
and toxic epidermal necrolysis, for
example, associated with neomycin
and sulnhonamides
 Epidemiology is the branch of medicine which deals with the incidence, distribution,
and possible control of diseases and other factors relating to health. ADRS are
widespread, as shown by both systematic reviews and large-scale studies. A review
of 69 studies from many countries in 2002 found that ADRS were responsible for an
estimated 2.6% of admissions to hospitals and that between 3.5% and 7.3% of in-
patients may suffer an ADR. A prospective study found that 6.5% out of 18,820
admissions to medical units were caused by ADRS, with 2.3% of patients dying as a
result. A similar prospective study of 3695 in- patient found that 14.7% of those
admitted to medical or surgical wards experienced an ADR during their stay. These
were more common in women, older patients and in those admitted to surgical
wards (Davies et al., 2009)
 Pharmacovigilance is defined as 'the study of the safety of
marketed drugs under the practical conditions of clinical use
in large communities'. Pharmacovigilance is concerned with
the detection, assessment and prevention of adverse effects
or any other possible drug-related problems, with the
ultimate goal of achieving rational and safe therapeutic
decisions in clinical practice.
 Spontaneous reporting
Pharmacovigilance uses multiple methods, but the following will focus on spontaneous reporting
systems. Spontaneous reporting systems collect data about suspected ADRs in a central database.
Cases are not collected in a systematic manner, but accumulate through reports submitted
spontaneously by people who make a connection between a drug and a suspected drug induced
event. In the UK, the spontaneous reporting scheme is the Yellow Card scheme. In some countries
reporting is a voluntary activity, in others reporting is a legal requirement.
Advantages:
- It is relatively cheap to administer,
- can follow a product throughout its life and
- can also accept reports to over-the-counter medication and herbal treatments.
Disadvantage:
- Their is inability to quantify the risk. Such systems supply a numerator (the number of reports), but
estimates of the incidence of reactions cannot be made because the population exposed to the
drug cannot be ascertained accurately.
 The UK's Yellow Card Scheme was established in 1964
following the thalidomide tragedy. The Scheme is
operated by the Medicines and Health care Products
Regulatory Authority (MHRA). Information from
Yellow Card reports is entered into a database,
suspected reactions are categorized using the
internationally accepted Medical Dictionary for
Regulatory Affairs (MedDRA) and the resultant signals
generated by the combined reports are then assessed
for causality.
 The thalidomide disaster is one
of the darkest episodes in
pharmaceutical research history.
The drug was marketed as a mild
sleeping pill safe even for
pregnant women. However, it
caused thousands of babies
worldwide to be born with
malformed limbs. The damage
was revealed in 1962.
 The first suspicions of a less common or unpredictable reaction may
often be seen in a case report from a practitioner. As seen by the
cases of thalidomide and practolol clinicians submitting case reports
to the medical press has been of importance in drug safety. Case
reports have been described as a form of non-systematic voluntary
reporting. Editors may demand a case series, requiring higher
standards of investigation than regulatory agencies demand from a
spontaneous report. These high standards can prevent case histories
from reaching publication. It takes time for a case report about a
suspected ADR to be published could be several months, during which
time more patients may be exposed to the potential risk.
 Cohort studies are prospective pharmaco-epidemiological studies
that monitor a large group of patients taking a particular drug over
a period of time. Ideally such studies compare the incidence of a
particular adverse event in two groups of patients, those taking the
drug of interest and, another group matched for all important
characteristics except the use of the drug. These studies can
indicate the relative risks associated with the adverse event in
people exposed to the drug being studied.
 Case - control studies compare the extent of drug usage in a group of patients who
have experienced the adverse event with the extent of usage among a matched
control group who are similar in potentially confounding factors, but have not
experienced the event. By comparing the prevalence of drug taking between the
groups, it may be possible to identify whether significantly more people who
experienced the event also took a particular drug. Examples of associations which
have been established by case control studies are Reye's syndrome (Reye's (Ryes)
syndrome is a rare but serious condition that causes swelling in the liver and brain.
Reye's syndrome most often affects children and teenagers.) And aspirin and the
relationship between maternal diethylstilboestrol ingestion and vaginal
adenocarcinoma in female offspring. Case - control studies are an effective method
of confirming whether or not 1.0ta drug causes a given reaction once a suspicion has
been raised.
Identifying and Assessing Standards in Clinical Practice.
Preventing ADRs
Monitoring Therapy
Explaining Risks to Patents
 The temporal relationship between the exposure to the drug and the subsequent event
 The clinical and pathological characteristics of the event - events which are known to be
related to drug use, rather than disease processes
 The pharmacological plausibility - based on the observer's knowledge of pharmacology
 Existing information in published drug information sources - whether or not the event has been
noted by others
 Concomitant medication - which may be considered the cause of an event
 Underlying and concurrent illnesses - may alter the event or be considered the cause of the
event
 De - challenge - disappearance of symptoms after dose reduction or cessation of therapy
 Re - challenge - reappearance of symptoms after dose increases or recommendation of therapy
 Patient characteristics and previous medical history - past history of the patient may color the
view of the event
 The potential for drug interactions.
Adverse Drug Reaction

More Related Content

What's hot

Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
Subhash Yende
 
Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)
faysalahmed35
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
Dr. Ramesh Bhandari
 
Clinical Pharmacy
Clinical Pharmacy Clinical Pharmacy
Clinical Pharmacy
MasudRana461
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
KRUSHNA ZAMBARE
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
Dr Manish Pal Singh
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
Ashwani Kumar Singh
 
Introduction to hospital pharmacy
Introduction to hospital pharmacyIntroduction to hospital pharmacy
Introduction to hospital pharmacy
Anas Bahnassi أنس البهنسي
 
History and progress of pharmacovigilance
History and progress of pharmacovigilanceHistory and progress of pharmacovigilance
History and progress of pharmacovigilance
Gagandeep Jaiswal
 
Rational use of otc medication
Rational use of otc medicationRational use of otc medication
Rational use of otc medication
Rafi Bhat
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
Urmila Aswar
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
Dr. Arun Sharma, MD
 
Drug distribution in hospital pharmacy
Drug distribution in hospital pharmacyDrug distribution in hospital pharmacy
Drug distribution in hospital pharmacy
Raju Sanghvi
 
Drug information final
Drug information finalDrug information final
Drug information final
Sitaram Khadka
 
Education and Training Program in the Hospital
Education and Training Program in the HospitalEducation and Training Program in the Hospital
Education and Training Program in the Hospital
Subhash Yende
 
14ab1t0024 roles and responsibilities of hospital pharmacist
14ab1t0024   roles and responsibilities of hospital pharmacist14ab1t0024   roles and responsibilities of hospital pharmacist
14ab1t0024 roles and responsibilities of hospital pharmacist
Ramesh Ganpisetti
 
Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)
Dr. Abhimanyu Prashar
 
Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
Subhash Yende
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
THUSHARA MOHAN
 
Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction
ReshmaManeDeshmukh
 

What's hot (20)

Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)Pharmacy and therapeutic committee(PTC)
Pharmacy and therapeutic committee(PTC)
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Clinical Pharmacy
Clinical Pharmacy Clinical Pharmacy
Clinical Pharmacy
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
Biopharmaceutics classification system
Biopharmaceutics classification systemBiopharmaceutics classification system
Biopharmaceutics classification system
 
Introduction to hospital pharmacy
Introduction to hospital pharmacyIntroduction to hospital pharmacy
Introduction to hospital pharmacy
 
History and progress of pharmacovigilance
History and progress of pharmacovigilanceHistory and progress of pharmacovigilance
History and progress of pharmacovigilance
 
Rational use of otc medication
Rational use of otc medicationRational use of otc medication
Rational use of otc medication
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Drug distribution in hospital pharmacy
Drug distribution in hospital pharmacyDrug distribution in hospital pharmacy
Drug distribution in hospital pharmacy
 
Drug information final
Drug information finalDrug information final
Drug information final
 
Education and Training Program in the Hospital
Education and Training Program in the HospitalEducation and Training Program in the Hospital
Education and Training Program in the Hospital
 
14ab1t0024 roles and responsibilities of hospital pharmacist
14ab1t0024   roles and responsibilities of hospital pharmacist14ab1t0024   roles and responsibilities of hospital pharmacist
14ab1t0024 roles and responsibilities of hospital pharmacist
 
Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)
 
Clinical Pharmacy
Clinical PharmacyClinical Pharmacy
Clinical Pharmacy
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
 
Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction
 

Similar to Adverse Drug Reaction

Adverse Drug Reaction.pptx
Adverse Drug Reaction.pptxAdverse Drug Reaction.pptx
Adverse Drug Reaction.pptx
Bimal Magar
 
adverse drug rxn.ppt
adverse drug rxn.pptadverse drug rxn.ppt
adverse drug rxn.ppt
Seema Bansal
 
Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ Classic
Joseph Gut
 
Adverse Drug Reactions.ppt
Adverse Drug Reactions.pptAdverse Drug Reactions.ppt
Adverse Drug Reactions.ppt
FarazaJaved
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
Michel Dumontier
 
Adverse Drug Reactions - Basics and Classification
Adverse Drug Reactions - Basics and ClassificationAdverse Drug Reactions - Basics and Classification
Adverse Drug Reactions - Basics and Classification
Venkateswaramurthy N
 
polypharmacy in older adults.pptx
polypharmacy in older adults.pptxpolypharmacy in older adults.pptx
polypharmacy in older adults.pptx
Hozaifa6
 
Ad rs ppt
Ad rs pptAd rs ppt
Ad rs ppt
Rafi Bhat
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
government medical college nagpur
 
Pharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug responsePharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug response
Narasimha Kumar G V
 
Adverse Drug Reaction and its reporting
Adverse Drug Reaction and its reporting Adverse Drug Reaction and its reporting
Adverse Drug Reaction and its reporting
MangeshBansod2
 
Drug Induced Liver Injury
Drug Induced Liver InjuryDrug Induced Liver Injury
Drug Induced Liver Injury
National Pharmacy Technician Association
 
DRUG INDUCED LIVER INJURY.pptx
DRUG INDUCED LIVER INJURY.pptxDRUG INDUCED LIVER INJURY.pptx
DRUG INDUCED LIVER INJURY.pptx
Sruthi Meenaxshi
 
An Update on Drug-induced Liver Injury
An Update on Drug-induced Liver InjuryAn Update on Drug-induced Liver Injury
An Update on Drug-induced Liver Injury
Jocelyn Red Red
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
Dr. Ramesh Bhandari
 
Pharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressentPharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressent
ismail sadek
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Akhil Joseph
 
Drug resistant epilepsy
Drug resistant epilepsyDrug resistant epilepsy
Drug resistant epilepsy
Mohammad A.S. Kamil
 
Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences
Ayesha Younas
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
iosrphr_editor
 

Similar to Adverse Drug Reaction (20)

Adverse Drug Reaction.pptx
Adverse Drug Reaction.pptxAdverse Drug Reaction.pptx
Adverse Drug Reaction.pptx
 
adverse drug rxn.ppt
adverse drug rxn.pptadverse drug rxn.ppt
adverse drug rxn.ppt
 
Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ Classic
 
Adverse Drug Reactions.ppt
Adverse Drug Reactions.pptAdverse Drug Reactions.ppt
Adverse Drug Reactions.ppt
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Adverse Drug Reactions - Basics and Classification
Adverse Drug Reactions - Basics and ClassificationAdverse Drug Reactions - Basics and Classification
Adverse Drug Reactions - Basics and Classification
 
polypharmacy in older adults.pptx
polypharmacy in older adults.pptxpolypharmacy in older adults.pptx
polypharmacy in older adults.pptx
 
Ad rs ppt
Ad rs pptAd rs ppt
Ad rs ppt
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Pharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug responsePharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug response
 
Adverse Drug Reaction and its reporting
Adverse Drug Reaction and its reporting Adverse Drug Reaction and its reporting
Adverse Drug Reaction and its reporting
 
Drug Induced Liver Injury
Drug Induced Liver InjuryDrug Induced Liver Injury
Drug Induced Liver Injury
 
DRUG INDUCED LIVER INJURY.pptx
DRUG INDUCED LIVER INJURY.pptxDRUG INDUCED LIVER INJURY.pptx
DRUG INDUCED LIVER INJURY.pptx
 
An Update on Drug-induced Liver Injury
An Update on Drug-induced Liver InjuryAn Update on Drug-induced Liver Injury
An Update on Drug-induced Liver Injury
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Pharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressentPharmacogenetics of antipsychotic and antidepressent
Pharmacogenetics of antipsychotic and antidepressent
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Drug resistant epilepsy
Drug resistant epilepsyDrug resistant epilepsy
Drug resistant epilepsy
 
Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences Adverse drug reactions attributed to genetic differences
Adverse drug reactions attributed to genetic differences
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
 

More from MdNazmulIslamTanmoy

Research Trends in Different Pharmaceutical Areas .pptx
Research Trends in Different Pharmaceutical Areas .pptxResearch Trends in Different Pharmaceutical Areas .pptx
Research Trends in Different Pharmaceutical Areas .pptx
MdNazmulIslamTanmoy
 
Parenteral products & Insulin
Parenteral products & InsulinParenteral products & Insulin
Parenteral products & Insulin
MdNazmulIslamTanmoy
 
COVID-19 treatment
COVID-19 treatmentCOVID-19 treatment
COVID-19 treatment
MdNazmulIslamTanmoy
 
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
MdNazmulIslamTanmoy
 
Deodorant , Antiperspirant, Perfume & Nail-polish.
Deodorant , Antiperspirant, Perfume & Nail-polish.Deodorant , Antiperspirant, Perfume & Nail-polish.
Deodorant , Antiperspirant, Perfume & Nail-polish.
MdNazmulIslamTanmoy
 
Carcinogenesis & Mechanism of DNA repair
Carcinogenesis & Mechanism of DNA repairCarcinogenesis & Mechanism of DNA repair
Carcinogenesis & Mechanism of DNA repair
MdNazmulIslamTanmoy
 
Hydrogels
HydrogelsHydrogels
Spermatogenesis steps, hormonal regulation and abnormalities
Spermatogenesis steps, hormonal regulation and abnormalitiesSpermatogenesis steps, hormonal regulation and abnormalities
Spermatogenesis steps, hormonal regulation and abnormalities
MdNazmulIslamTanmoy
 
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
MdNazmulIslamTanmoy
 
New product launching (Spli2 water purifier)
New product launching (Spli2 water purifier)New product launching (Spli2 water purifier)
New product launching (Spli2 water purifier)
MdNazmulIslamTanmoy
 
Diflunisal in geriatric
Diflunisal in geriatricDiflunisal in geriatric
Diflunisal in geriatric
MdNazmulIslamTanmoy
 
Introduction to biopharmaceutics (Part:05)
Introduction to biopharmaceutics (Part:05)Introduction to biopharmaceutics (Part:05)
Introduction to biopharmaceutics (Part:05)
MdNazmulIslamTanmoy
 
Introduction to biopharmaceutics (part:04)
Introduction to biopharmaceutics (part:04)Introduction to biopharmaceutics (part:04)
Introduction to biopharmaceutics (part:04)
MdNazmulIslamTanmoy
 
Introduction to biopharmaceutics (Part:02)
Introduction to biopharmaceutics (Part:02)Introduction to biopharmaceutics (Part:02)
Introduction to biopharmaceutics (Part:02)
MdNazmulIslamTanmoy
 
Introduction to biopharmaceutics (part:03)
Introduction to biopharmaceutics (part:03)Introduction to biopharmaceutics (part:03)
Introduction to biopharmaceutics (part:03)
MdNazmulIslamTanmoy
 
Introduction to biopharmaceutics (Part:01)
Introduction to biopharmaceutics (Part:01)Introduction to biopharmaceutics (Part:01)
Introduction to biopharmaceutics (Part:01)
MdNazmulIslamTanmoy
 
NSAIDs (Non-steroidal anti-inflammatory drugs)
NSAIDs (Non-steroidal anti-inflammatory drugs)NSAIDs (Non-steroidal anti-inflammatory drugs)
NSAIDs (Non-steroidal anti-inflammatory drugs)
MdNazmulIslamTanmoy
 
Liver & Liver Diseases
Liver &  Liver DiseasesLiver &  Liver Diseases
Liver & Liver Diseases
MdNazmulIslamTanmoy
 
Non-steroidal anti-inflammatory drugs (NSAID)
Non-steroidal anti-inflammatory drugs (NSAID)Non-steroidal anti-inflammatory drugs (NSAID)
Non-steroidal anti-inflammatory drugs (NSAID)
MdNazmulIslamTanmoy
 
HPLC
HPLCHPLC

More from MdNazmulIslamTanmoy (20)

Research Trends in Different Pharmaceutical Areas .pptx
Research Trends in Different Pharmaceutical Areas .pptxResearch Trends in Different Pharmaceutical Areas .pptx
Research Trends in Different Pharmaceutical Areas .pptx
 
Parenteral products & Insulin
Parenteral products & InsulinParenteral products & Insulin
Parenteral products & Insulin
 
COVID-19 treatment
COVID-19 treatmentCOVID-19 treatment
COVID-19 treatment
 
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)Biopharmaceutics & Pharmacokinetics (Ultimate final note)
Biopharmaceutics & Pharmacokinetics (Ultimate final note)
 
Deodorant , Antiperspirant, Perfume & Nail-polish.
Deodorant , Antiperspirant, Perfume & Nail-polish.Deodorant , Antiperspirant, Perfume & Nail-polish.
Deodorant , Antiperspirant, Perfume & Nail-polish.
 
Carcinogenesis & Mechanism of DNA repair
Carcinogenesis & Mechanism of DNA repairCarcinogenesis & Mechanism of DNA repair
Carcinogenesis & Mechanism of DNA repair
 
Hydrogels
HydrogelsHydrogels
Hydrogels
 
Spermatogenesis steps, hormonal regulation and abnormalities
Spermatogenesis steps, hormonal regulation and abnormalitiesSpermatogenesis steps, hormonal regulation and abnormalities
Spermatogenesis steps, hormonal regulation and abnormalities
 
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
Enzyme catalysed reactions, enzyme kinetics and it’s mechanism of action.
 
New product launching (Spli2 water purifier)
New product launching (Spli2 water purifier)New product launching (Spli2 water purifier)
New product launching (Spli2 water purifier)
 
Diflunisal in geriatric
Diflunisal in geriatricDiflunisal in geriatric
Diflunisal in geriatric
 
Introduction to biopharmaceutics (Part:05)
Introduction to biopharmaceutics (Part:05)Introduction to biopharmaceutics (Part:05)
Introduction to biopharmaceutics (Part:05)
 
Introduction to biopharmaceutics (part:04)
Introduction to biopharmaceutics (part:04)Introduction to biopharmaceutics (part:04)
Introduction to biopharmaceutics (part:04)
 
Introduction to biopharmaceutics (Part:02)
Introduction to biopharmaceutics (Part:02)Introduction to biopharmaceutics (Part:02)
Introduction to biopharmaceutics (Part:02)
 
Introduction to biopharmaceutics (part:03)
Introduction to biopharmaceutics (part:03)Introduction to biopharmaceutics (part:03)
Introduction to biopharmaceutics (part:03)
 
Introduction to biopharmaceutics (Part:01)
Introduction to biopharmaceutics (Part:01)Introduction to biopharmaceutics (Part:01)
Introduction to biopharmaceutics (Part:01)
 
NSAIDs (Non-steroidal anti-inflammatory drugs)
NSAIDs (Non-steroidal anti-inflammatory drugs)NSAIDs (Non-steroidal anti-inflammatory drugs)
NSAIDs (Non-steroidal anti-inflammatory drugs)
 
Liver & Liver Diseases
Liver &  Liver DiseasesLiver &  Liver Diseases
Liver & Liver Diseases
 
Non-steroidal anti-inflammatory drugs (NSAID)
Non-steroidal anti-inflammatory drugs (NSAID)Non-steroidal anti-inflammatory drugs (NSAID)
Non-steroidal anti-inflammatory drugs (NSAID)
 
HPLC
HPLCHPLC
HPLC
 

Recently uploaded

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 

Recently uploaded (20)

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 

Adverse Drug Reaction

  • 2.  An ADR as “ a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis , diagnosis or therapy of disease , or for modification of physiological function ( WHO , 1972 ) .
  • 3.  Rawlins-Thompson classification  The Rawlins-Thompson system of classification divides ADRS into two main groups: Type A and Type B (Rawlins, 1981).  Type A reactions are the normal, but quantitatively exaggerated, pharmacological effects of a drug. They include the primary pharmacological effect of the drug, as well as any secondary pharmacological effects of the drug, for example, ADRS caused by the antimuscarinic activity of tricyclic antidepressants. Type A reactions are most common, accounting for 80% of reactions.
  • 4. Types of reaction Features Examples Type A: Augmented pharmacological effect Common, predictable effect, Dose dependent, Low morbidity, Low mortality Bradycardia associated with a beta- adrenergic receptor antagonist Type B: Bizzare effects not related to pharmacological effect Uncommon, Unpredictable, Not dose dependent, High morbidity, High mortality Anaphylaxis associated with a penicillin antibiotic Type C: Dose-related and time- related Uncommon, Related to the cumulative dose Hypothalamic pituitary- adrenal axis suppression by corticosteroids Type D: Time related Uncommon, Usually dose related, Occurs or becomes apparent some time after use of the drug Carcinogenesis Type E: Withdrawal Uncommon, Occurs soon after withdrawal Opiate withdrawal syndrome Type F: Unexpected failure of therapy Common, Dose- related, Often cause by drug interactions Failure of oral contraceptive in presence of enzyme inducer
  • 5. Dose relatedness Time relatedness Susceptibility Toxic effects: ADR S that occur at doses higher than the usual therapeutic dose Collateral effects: ADR s that occur at standard therapeutic doses Hyper-susceptibility reactions: ADRS that occur at sub- therapeutic doses in susceptible Patients Time-independent reactions: ADR s that occur at any time during treatment. Time-dependent reactions: Rapid reactions occur when a drug is administered too rapidly. Early reactions occur early in treatment then abate with continuing treatment (tolerance). Intermediate reactions occur after some delay, but if reaction does not occur after a certain time, little or no risk exists. Late reactions risk of ADR increases with continued- to-repeated exposure, including withdrawal reactions. Delayed reactions occur some time after exposure, even if the drug is withdrawn before the ADR occurs. Raised susceptibility may be present in some individuals, but not others. Alternatively, susceptibility may follow a continuous distribution - increasing susceptibility with impaired renal function. Factors include: genetic variation, age, sex, altered physiology, exogenous factors (interactions) and disease.
  • 6. A number of general factors which affect susceptibility to ADRS and others which affect the propensity of specific drugs to cause ADRS have been elucidated. (i) Age (ii) Gender (iii) Co-morbidities and concomitant medicines use (iv) Ethnicity (v) Pharmacogenetics (vi) Erythrocyte glucose-6-phosphatase dehydrogenase (G6PD) deficiency (vii) Porphyrias
  • 7.  Elderly patients may be more prone to ADRS, with age- related decline in both the metabolism and elimination of drugs from the body. They also have multiple cos morbidities and are, therefore, exposed to more prescribed drugs. Children differ from adults in their response to drugs. Neonatal differences in body composition, metabolism and other physiological parameters can increase the risk of specific adverse reactions. Differences in drug metabolism and elimination and end-organ responses can also increase the risk. Chloramphenicol, digoxin, and ototoxic antibiotics such as streptomycin are examples of drugs that have a higher risk of toxicity in the first weeks of life.
  • 8.  Women may be more susceptible to ADRS. In addition, there are particular adverse reactions that appear to be more common in women than men. For example, impairment of concentration and psychiatric adverse events associated with the anti-malarial mefloquine are more common in females. Females are more susceptible to drug-induced torsade de pointes, a ventricular arrhythmia linked to ventricular fibrillation and death. Women are also over-represented in reports of torsades de pointes associated with cardiovascular drugs (such as sotalol) and erythromycin. This increased susceptibility in women is thought to be due to their longer QTc interval compared to mên.
  • 9.  In cardiology, the QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. A lengthened QT interval is a marker for the potential of ventricular tachyarrhythmias like torsades de pointes and a risk factor for sudden death.  Torsades de pointes (TdP) is a specific form of polymorphic ventricular tachycardia occurring in the context of QT prolongation; it has a characteristic morphology in which the QRS complexes "twist" around the isoelectric line. For TdP to be diagnosed, the patient has to have evidence of both PVT and QT prolongation.
  • 10.  Reductions in hepatic and renal function substantially increase the risk of ADRSs. A recent study examining factors that predicted repeat admissions to hospital with ADRS in older patients showed that co-morbidities such as congestive cardiac failure, diabetes, and peripheral vascular, chronic pulmonary, rheumatological, hepatic, renal, and malignant diseases were strong predictors of readmissions for ADRS, while advancing age was not. Reasons for this could be pharmacokinetic and pharmacodynamic changes associated with pulmonary, cardiovascular, renal and hepatic insufficiency, or drug interactions because of multiple drag therapy.
  • 11.  Ethnicity is the fact or state of belonging to a social group that has a common national or cultural tradition. It has also been linked to susceptibility to ADRS, due to inherited traits of metabolism. For example, that the cytochrome P450 genotype, involved in drug metabolism, has varied distribution among people of differing ethnicity (CYP2C9 alleles associated with poor metabolism can affect warfarin metabolism and increase the risk of toxicity). This occurs more frequently in white individuals compared to black individuals. - Examples of ADRS linked to ethnicity include the increased risk of angioedema with the use of ACE inhibitors in black patients, - the increased propensity of white and black patients to experience central nervous system ADRS associated with mefloquine compared to patients of Chinese or Japanese origin, - differences in the pharmacokinetics of rosuvastatin in Asian patients which may expose them to an increased risk of myopathy.
  • 12.  Pharmacogenetics is the study of inherited genetic |differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects. It influence an individual's response to drugs, and examines polymorphisms that code for drug transporters, drug- metabolising enzymes and drug receptors. Examples of pharmacogenetics are hypersensitivity reactions to abacavir used in the treatment of HIV and cutaneous ADRS Steven- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) to antiepileptic drugs such as carbamazepine and phenytoin.
  • 13.  Glucose-6-phosphate dehydrogenase deficiency (G6PDD) is an inborn error of metabolism that predisposes to red blood cell breakdown. Most of the time, those who are affected have no symptoms. Following a specific trigger, symptoms such as yellowish skin, dark urine, shortness of breath, and feeling tired may develop. G6PD deficiency is present in over 400 million people worldwide. It is a sex- linked inherited enzyme deficiency, leading to susceptibility to haemolytic anaemia. Patients with low levels of G6PD are predisposed to haemolysis with oxidant drugs such as primaquine, sulphonamides and nitrofurantoin.
  • 14.  Porphyrins are a group of heterocyclic macrocycle organic compoupds, composed of four modified pyrrole subunits interconnected at their a carbon atoms via methine bridges. These disorders are usually inherited, meaning they are caused by abnormalities in genes passed from parents to children. When a person has a porphyria, cells fail to change body chemicals called porphyrins and porphyrin precursors into heme, the substance that gives blood its red color. The porphyrias are a heterogeneous group of inherited disorders of haem biosynthesis. The effects of drugs are of most importance in patients with acute porphyrias, in which certain commonly prescribed agents may precipitate life-threatening attacks. Other trigger factors include alcohol and changes in sex hormone balance. In the acute porphyrias, patients develop abdominal and neuropsychiatric disturbances, and they excrete in their urine excessive amounts of the porphyrin precursors 5- aminolaevulinic acid (ALA) and porphobilinogen.
  • 15.  Immunologic response - a bodily defense reaction that recognizes an invading substance (an antigen: such as a virus or fungus or bacteria or transplanted organ) and produces antibodies specific against that antigen. immune reaction, immune response. The immune system is able to recognize drugs as foreign substances, leading to allergic reactions. Smaller drug molecules (<600 Da) can bind with proteins to trigger an immune response, or larger molecules can trigger an immune response directly. The immune response is not related to the pharmacological action of the drug and prior exposure to the drug is required. Immunological reactions are often distinct recognizable responses. Allergic reactions range from rashes, serum sickness and angioedema to the life-threatening bronchospasm and hypotension associated with anaphylaxis. Patients with a history of atopic or allergic disorders are at higher risk. Immunological (hypersensitivity) reactions are split into four main types.
  • 16. Classification Mechanism Symptoms/signs and examples Type I (immediate) Drug/lgE complex to mast cells release of histamine and leukotrienes. Symptoms/signs and examples Pruritis, urticaria, bronchoconstriction, angioedema, hypotension, shock, for example, penicillin anaphylaxis. Type II (cytotoxic) IgG and complement binding to (usually) red blood cell. Cytotoxic T- cells lyse the cell. Haemolytic anaemia and thrombocytopaenia, for example, associated with cephalosporins, penicillins and rifampicin. Type II (immune complex) Drug antigen and I gG or I gM form immune complex, attracting macrophages and complement activation. Cutaneous vasculitis, serum sickness, for example, associated with chlorpromazine and sulphonamides Type IV (delayed type) Antigen presentation with major histocompatibility complex protein to T-cells and cytokine and inflammatory mediator release. Usually occur after 7-20 days. Macular rashes and organ failure, including Stevens-Johnson syndrome and toxic epidermal necrolysis, for example, associated with neomycin and sulnhonamides
  • 17.  Epidemiology is the branch of medicine which deals with the incidence, distribution, and possible control of diseases and other factors relating to health. ADRS are widespread, as shown by both systematic reviews and large-scale studies. A review of 69 studies from many countries in 2002 found that ADRS were responsible for an estimated 2.6% of admissions to hospitals and that between 3.5% and 7.3% of in- patients may suffer an ADR. A prospective study found that 6.5% out of 18,820 admissions to medical units were caused by ADRS, with 2.3% of patients dying as a result. A similar prospective study of 3695 in- patient found that 14.7% of those admitted to medical or surgical wards experienced an ADR during their stay. These were more common in women, older patients and in those admitted to surgical wards (Davies et al., 2009)
  • 18.  Pharmacovigilance is defined as 'the study of the safety of marketed drugs under the practical conditions of clinical use in large communities'. Pharmacovigilance is concerned with the detection, assessment and prevention of adverse effects or any other possible drug-related problems, with the ultimate goal of achieving rational and safe therapeutic decisions in clinical practice.
  • 19.  Spontaneous reporting Pharmacovigilance uses multiple methods, but the following will focus on spontaneous reporting systems. Spontaneous reporting systems collect data about suspected ADRs in a central database. Cases are not collected in a systematic manner, but accumulate through reports submitted spontaneously by people who make a connection between a drug and a suspected drug induced event. In the UK, the spontaneous reporting scheme is the Yellow Card scheme. In some countries reporting is a voluntary activity, in others reporting is a legal requirement. Advantages: - It is relatively cheap to administer, - can follow a product throughout its life and - can also accept reports to over-the-counter medication and herbal treatments. Disadvantage: - Their is inability to quantify the risk. Such systems supply a numerator (the number of reports), but estimates of the incidence of reactions cannot be made because the population exposed to the drug cannot be ascertained accurately.
  • 20.  The UK's Yellow Card Scheme was established in 1964 following the thalidomide tragedy. The Scheme is operated by the Medicines and Health care Products Regulatory Authority (MHRA). Information from Yellow Card reports is entered into a database, suspected reactions are categorized using the internationally accepted Medical Dictionary for Regulatory Affairs (MedDRA) and the resultant signals generated by the combined reports are then assessed for causality.
  • 21.  The thalidomide disaster is one of the darkest episodes in pharmaceutical research history. The drug was marketed as a mild sleeping pill safe even for pregnant women. However, it caused thousands of babies worldwide to be born with malformed limbs. The damage was revealed in 1962.
  • 22.  The first suspicions of a less common or unpredictable reaction may often be seen in a case report from a practitioner. As seen by the cases of thalidomide and practolol clinicians submitting case reports to the medical press has been of importance in drug safety. Case reports have been described as a form of non-systematic voluntary reporting. Editors may demand a case series, requiring higher standards of investigation than regulatory agencies demand from a spontaneous report. These high standards can prevent case histories from reaching publication. It takes time for a case report about a suspected ADR to be published could be several months, during which time more patients may be exposed to the potential risk.
  • 23.  Cohort studies are prospective pharmaco-epidemiological studies that monitor a large group of patients taking a particular drug over a period of time. Ideally such studies compare the incidence of a particular adverse event in two groups of patients, those taking the drug of interest and, another group matched for all important characteristics except the use of the drug. These studies can indicate the relative risks associated with the adverse event in people exposed to the drug being studied.
  • 24.  Case - control studies compare the extent of drug usage in a group of patients who have experienced the adverse event with the extent of usage among a matched control group who are similar in potentially confounding factors, but have not experienced the event. By comparing the prevalence of drug taking between the groups, it may be possible to identify whether significantly more people who experienced the event also took a particular drug. Examples of associations which have been established by case control studies are Reye's syndrome (Reye's (Ryes) syndrome is a rare but serious condition that causes swelling in the liver and brain. Reye's syndrome most often affects children and teenagers.) And aspirin and the relationship between maternal diethylstilboestrol ingestion and vaginal adenocarcinoma in female offspring. Case - control studies are an effective method of confirming whether or not 1.0ta drug causes a given reaction once a suspicion has been raised.
  • 25. Identifying and Assessing Standards in Clinical Practice. Preventing ADRs Monitoring Therapy Explaining Risks to Patents
  • 26.  The temporal relationship between the exposure to the drug and the subsequent event  The clinical and pathological characteristics of the event - events which are known to be related to drug use, rather than disease processes  The pharmacological plausibility - based on the observer's knowledge of pharmacology  Existing information in published drug information sources - whether or not the event has been noted by others  Concomitant medication - which may be considered the cause of an event  Underlying and concurrent illnesses - may alter the event or be considered the cause of the event  De - challenge - disappearance of symptoms after dose reduction or cessation of therapy  Re - challenge - reappearance of symptoms after dose increases or recommendation of therapy  Patient characteristics and previous medical history - past history of the patient may color the view of the event  The potential for drug interactions.